BPC-157, TB-500 & 'Healing Peptides'
The grey-market repair narrative — what the rat data show, what humans don't have.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Summarize the preclinical case for BPC-157 in tendon/ligament/gut healing.
- L02Explain why no FDA-approved human use exists.
- L03Counsel an athlete on regulatory and contamination risks.
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
BPC-157 is sold as a 'healing peptide' for tendon, ligament, and gut injury. The animal studies look exciting; human studies essentially don't exist. The product you'd buy is also not regulated for purity.
Most patients asking come from athletic, biohacker, or post-injury populations. Frame the conversation around: (1) absent human evidence, (2) contamination/purity, (3) WADA risk if relevant, (4) what proven alternatives exist (loading protocols, PRP for select tendinopathies).
Sikiric's group has produced most of the BPC-157 corpus; replication outside the originating lab is sparse. The pentadecapeptide's stability in gastric juice is one of the few unusual mechanistic claims that could justify an oral formulation if ever properly studied.
BPC-157 is 'safe because it's a fragment of stomach protein'.
Endogenous origin says nothing about pharmacological dose safety. Insulin is endogenous; an overdose kills you.
What the data say
Apply it
42-year-old runner with 8 months of Achilles tendinopathy. Failed eccentric loading, considering PRP. Saw a clinic offering BPC-157 injections at $400/cycle. Asks your opinion.
- A.Endorse — preclinical data are strong
- Explain that human evidence is essentially absent, the compounded product has no purity oversight, and recommend continued evidence-based care (loading progression, PRP if appropriate)
- C.Refuse to discuss
- D.Recommend oral BPC-157 supplements as safer
Test yourself
Lock it in — review what's due
Sources cited in this module
- [1]Category 2 list — bulk drug substances under 503A (includes ipamorelin, CJC-1295, BPC-157)FDA Pharmacy Compounding Advisory Committee · 2023Regulatory · T1
- [2]Brain–gut Axis and Pentadecapeptide BPC 157Sikiric P. et al. · Current Neuropharmacology · 2018Review · T3
- [3]The promoting effect of pentadecapeptide BPC 157 on tendon healingChang CH. et al. · Journal of Applied Physiology · 2014Mechanism / preclinical · T3
- [4]Thymosin β4: Structure, function, and biological propertiesGoldstein AL, Hannappel E, Sosne G, Kleinman HK · Annals NY Acad Sci · 2012Review · T3